HOUSE BILL 1207

By: Delegates Beitzel, Hill, and A. Miller
Introduced and read first time: February 8, 2018
Assigned to: Health and Government Operations

A BILL ENTITLED

AN ACT concerning

Public Health – Ibogaine Treatment Study Program

FOR the purpose of establishing the Ibogaine Treatment Study Program in the Maryland
Department of Health; providing for the purpose of the Program; requiring the
Department, on or before a certain date, to select a certain number of academic
medical centers to participate in the Program on or before a certain date; requiring
the Department to provide funding to academic medical centers selected to
participate in the Program to conduct a certain study for a certain period of time;
requiring the Governor to include in the annual budget for certain fiscal years a
certain appropriation for the Program; requiring that certain unexpended funds
revert to the General Fund; requiring the Department to report to the Governor and
the General Assembly certain findings and recommendations on or before a certain
date; defining certain terms; providing for the termination of this Act; and generally
relating to the Ibogaine Treatment Study Program.

BY adding to
Article – Health – General
Section 8–1201 through 8–1205 to be under the new subtitle “Subtitle 12.
Ibogaine Treatment Study Program”
Annotated Code of Maryland
(2015 Replacement Volume and 2017 Supplement)

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
That the Laws of Maryland read as follows:

Article – Health – General

SUBTITLE 12. IBOGAINE TREATMENT STUDY PROGRAM.

8–1201.
(A) In this subtitle the following words have the meanings indicated.

(B) “Academic medical center” has the meaning stated in § 13–3301 of this article.

(C) “Ibogaine” means the naturally occurring psychoactive substance found in the root bark of the iboga plant.

(D) “Ibogaine treatment” means the administering or dispensing of ibogaine by a health care practitioner in a health care facility to opioid–dependent individuals.

(E) (1) “Opioid dependence” has the meaning stated in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the American Psychiatric Association.

(2) “Opioid dependence” includes:

   (i) A maladaptive pattern of substance use leading to clinically significant impairment or distress; and

   (ii) A combination of several of the following signs and symptoms:

       1. Increasing drug tolerance;

       2. Withdrawal signs and symptoms;

       3. A desire or unsuccessful effort to cut down or control substance use;

       4. Loss of social, occupational, or recreational activities because of substance use; and

       5. Continuing substance use despite consequences.

(F) “Opioid–dependent individual” means an individual who has an opioid dependence.

(G) “Program” means the Ibogaine Treatment Study Program
ESTABLISHED UNDER THIS SUBTITLE.

(A) THERE IS AN IBOGAINE TREATMENT STUDY PROGRAM IN THE DEPARTMENT.

(B) THE PURPOSE OF THE PROGRAM IS TO:

(1) EVALUATE THE EFFECTIVENESS AND SAFETY OF IBOGAINE TREATMENT FOR OPIOID DEPENDENCE; AND

(2) COMPARE THE EFFECTIVENESS OF IBOGAINE TREATMENT WITH CONVENTIONAL TREATMENT METHODS AND INTERVENTIONS, INCLUDING OPIOID REPLACEMENT THERAPY.

ON OR BEFORE JULY 1, 2019, THE DEPARTMENT SHALL SELECT ONE OR MORE ACADEMIC MEDICAL CENTERS TO PARTICIPATE IN THE PROGRAM.

(B) THE DEPARTMENT SHALL PROVIDE FUNDING TO ACADEMIC MEDICAL CENTERS SELECTED TO PARTICIPATE IN THE PROGRAM TO CONDUCT A 2–YEAR STUDY OF IBOGAINE TREATMENT.

(A) FOR FISCAL YEAR 2020 AND FISCAL YEAR 2021, THE GOVERNOR SHALL INCLUDE IN THE ANNUAL BUDGET AN APPROPRIATION OF $250,000 FOR THE PROGRAM.

(B) ANY FUNDS APPROPRIATED UNDER SUBSECTION (A) OF THIS SECTION THAT ARE NOT EXPENDED FOR THE PROGRAM AT THE END OF FISCAL YEAR 2021 SHALL REVERT TO THE GENERAL FUND.

ON OR BEFORE DECEMBER 1, 2021, THE DEPARTMENT SHALL REPORT TO THE GOVERNOR AND, IN ACCORDANCE WITH § 2–1246 OF THE STATE GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY ON THE FINDINGS AND RECOMMENDATIONS FROM THE PROGRAM.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 1, 2018. It shall remain effective for a period of 4 years and, at the end of June 30, 2022,
this Act, with no further action required by the General Assembly, shall be abrogated and of no further force and effect.